Cue Biopharma
64 hedge funds and large institutions have $28.7M invested in Cue Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 31 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
58% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 31
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Holders
64
Holding in Top 10
–
Calls
$87K
Puts
$42K
Top Buyers
| 1 | +$266K | |
| 2 | +$223K | |
| 3 | +$194K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$193K |
| 5 |
AC
Annandale Capital
Dallas,
Texas
|
+$145K |
Top Sellers
| 1 | -$508K | |
| 2 | -$478K | |
| 3 | -$402K | |
| 4 |
Millennium Management
New York
|
-$361K |
| 5 |
Renaissance Technologies
New York
|
-$342K |